Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,447 signal articles · 144 in last 24h · 154,069 total before filter · latest 25m ago
144last 24h
877last 7d
146● bullish (7d)
99● bearish (7d)
214publishers
AllMacro208Earnings108M&A125Regulatory22Product21Analyst17
✕ clear all filtersticker: IEXSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Is Strong Q2 Guidance And Dividend Consistency Reshaping The Investment Case For IDEX (IEX)?
Simply Wall St.1d agoneutral
Is Strong Q2 Guidance And Dividend Consistency Reshaping The Investment Case For IDEX (IEX)?

IDEX Corporation’s Board approved a regular quarterly cash dividend of US$0.73 per share, paid on October 16, 2026, marking the company’s 128th consecutive regular quarterly dividend and reinforcing its long-running pattern of returning cash to shareholders. This announcement came shortly after IDEX’s Q2 2026 results exceeded expectations and management raised full-year guidance, supported by strong demand from data centers, semiconductors, and space and defense markets within its Health &...

3 Unpopular Stocks with Open Questions
StockStory36d agoneutral
3 Unpopular Stocks with Open Questions

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

IDEX (IEX) Rides A Strong Narrative, Is It Still Below Fair Value?
Simply Wall St.39d agoneutral
IDEX (IEX) Rides A Strong Narrative, Is It Still Below Fair Value?

IDEX (IEX) has delivered a 47.17% total return over the past year, supported by reported annual revenue of US$3.59b and net income of US$519.5m, which gives investors concrete figures to assess the stock. See our latest analysis for IDEX. Over the past year, IDEX’s share price return has been strong, with a 33.44% year to date gain and a 14.53% 3 month share price return indicating building momentum in addition to its 47.17% 1 year total shareholder return. If you are interested in what else...

1 Mid-Cap Stock to Consider Right Now and 2 We Ignore
StockStory42d agoneutral
1 Mid-Cap Stock to Consider Right Now and 2 We Ignore

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More
24/7 Wall St.43d agoneutral
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More

With CPI dropping at 8:30 AM and the Strait of Hormuz near shutdown, Wall Street faces a pivotal morning that could swing stocks sharply in either direction, and analysts at Deutsche Bank, Oppenheimer, Berenberg, and others are already repositioning ahead of the numbers.